Men's Health: Recent Episodes
ReachMD
Host: Jennifer Caudle, DO
Guest: Geoffrey B. Johnson, M.D., Ph.D.
Prostate-specific membrane antigen (PSMA) PET scans are a method by which clinicians can see if a patient who is suffering from prostate cancer has tumors that are expressing the PSMA target. In addition to that, the scan allows us to measure how much of the medication we get onto that cancer target and if it’s going to be effective. Take a deep dive with Dr. Jennifer Caudle as she speaks with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota, who also presented this research at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.
Guest: Geoffrey B. Johnson, M.D., Ph.D.
When looking at patients who suffer from prostate cancer who are receiving PSMA therapy, we can see on our images that the medication not only goes to their cancer, but it also goes to some other things in their body, including the salivary glands. To learn more about his recent study on salivary toxicity, join Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Victoria Leavitt, PhD
Disease-modifying therapies (DMTs) are an effective option for patients with multiple sclerosis (MS). In fact, a recent study presented at the 2023 joint ECTRIMS-ACTRIMS meeting in Italy found that MS patients being treated with a DMT had better cognitive function than those who were not. However, the same study also found that women are less likely than men to receive DMT treatment. Dive further into the findings with Dr. Andrew Wilner and Dr. Victoria Leavitt, Assistant Professor of Neuropsychology at Columbia University.
Guest: Alan Bryce, MD
Lutetium-177and radium-223 have both been shown to significantly improve survival in patients with metastatic castration-resistant prostate cancer, but how do these treatment options compare? Find out with Dr. Alan Bryce, who presented a session on this exact topic at the 2024 ASCO Genitourinary Cancers Symposium.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Neeraj Agarwal, MD, FASCO
TALAPRO-2 was a recent phase 3 study conducted in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting. Patients were randomized to receive either enzalutamide plus talazoparib or enzalutamide plus placebo, and the researchers found that there was a 37 percent reduction in risk of progression or death among those who received enzalutamide plus talazoparib. Dive further into the findings and their implications for patients with mCRPC with Dr. Charles Turck and Dr. Neeraj Agarwal, Professor of Medicine at the Huntsman Cancer Institute at the University of Utah.
Host: Rishi Sekar, MD
A recent study sought to investigate why there are disparities in mortality as well as access and participation in clinical trials among vulnerable prostate cancer populations. According to the findings, counties in the United States that had the highest prostate cancer mortality were less likely to have any clinical trials in the area. Dive further into the results with Dr. Rishi Sekar, who presented the “Disparities in Prostate Cancer Mortality and Clinical Trial Availability Across Vulnerable Populations” session at the 2024 ASCO Genitourinary Cancers Symposium.
Host: Zachery Reichert MD, PhD
If hormonal therapies are not working for prostate cancer patients, chemotherapy may be a reliable alternative based on findings from a recent study. In fact, out of the 70 percent of patients who had pain when entering the study, 45 percent had their pain improved with chemotherapy. Dive more into the findings with Dr. Zachery Reichert, who presented the “Sequencing Hormonal Therapies After Treatment Intensification” session at the 2024 ASCO Genitourinary Cancers Symposium.
Guest: Caron A. Jacobson, MD
CD19-directed chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment of aggressive non-Hodgkin lymphoma (NHL), offering patients with refractory/relapsed disease the chance for a potential cure after a single infusion. However, the widespread use of CAR T-cell therapies faces several challenges, from the production of the therapies to the management of toxicities to issues of inpatient vs outpatient administration. While CAR T-cell therapies have historically been given in the inpatient setting, interest in outpatient delivery is growing, and this option may become more feasible if logistical issues and lack of multidisciplinary collaboration between the community provider and the CAR-T cell therapy center can be overcome.
AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer, helping to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on CAR T-cell therapies in large B-cell lymphoma regarding practical considerations for CAR T-cell therapies.
Guest: Jessica E. Hawley M.D. M.S.
For patients who start out with hormone sensitive prostate cancer, there's a period of time where the prostate cancer cells are responsive to suppressing testosterone production. So there’s a nice disease response early in that time period after diagnosis and when initial treatment has begun, but how long is each patient going to respond to that initial treatment, and what role does the multidisciplinary team have? Dive in with Dr. Jessica Hawley, Medical Oncologist at Fred Hutch Cancer Center and an Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine.
Host: Neal Shore, MD
Between 20 and 50 percent of patients with high-risk localized prostate cancer will develop biochemical resistance, but historically, no Level I evidence for treatment was available. That’s why the EMBARK study is the first phase 3 trial to develop Level I evidence looking at monotherapy T suppression versus monotherapy enzalutamide versus combination enzalutamide and leuprolide. Dive into the findings with Dr. Neal Shore, who presented the “Outcomes of Men with High-Risk Biochemically Recurrent Prostate Cancer Who Suspended Enzalutamide Monotherapy Treatment in the Phase 3 EMBARK Study” session at the 2024 ASCO Genitourinary Cancers Symposium.
Host: Daniel Kwon, MD
Between patient anxiety and insurance implications, there are several challenges associated with delivering germline testing to veterans with advanced prostate cancer. Learn more about these challenges and proposed solutions with Dr. Daniel Kwon, who presented the “Challenges in Patient-Centered Germline Testing Delivery for Veterans with Advanced Prostate Cancer” session at the 2024 ASCO Genitourinary Cancers Symposium.
Guest: Jessica E. Hawley M.D. M.S.
The National Comprehensive Cancer Network (NCCN) has recommended new guidelines for the treatment of prostate Cancer. In this episode, you’ll learn about the top three biggest changes to the NCCN guidelines. Tune in with Dr. Jessica Hawley, Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, who will also present this topic at the ASCO GU Symposium 2024.
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Frank dela Rama, RN, MS, AOCNS, AGN-BC
Learn about the APP’s evolving role in caring for patients receiving PARP inhibitors for prostate cancer in this on-demand webcast capturing a live presentation by Clinical Nurse Specialist Frank dela Rama, RN, MS, AOCNS, AGN-BC.
Guest: Neeraj Agarwal, MD, FASCO
Guest: Elena Castro, MD, PhD
Guest: Neal Shore, MD, FACS
Guest: Axel S. Merseburger, MD
While the development of advanced prostate cancers is largely influenced by androgen receptor (AR) signaling, DNA-damage response (DDR) pathways also contribute to disease progression. AR axis-targeted therapies (ARATs) have been the standard of care for first-line mCRPC. Inhibiting PARP activity is an effective strategy for targeting malignant cells with limited DNA repair capacity due to DDR gene mutations, leading to synthetic lethality. There may be a synergy between ARATs and PARP inhibitors (PARPi), as ARATs can induce HRR deficiencies and PARP inhibitors can increase the activity of ARATs through AR-dependent transcription. Recent clinical trial results have demonstrated that the combination of PARPi with ARATs is safe and effective for the first-line treatment of patients with mCRPC, with 3 combinations now FDA-approved: olaparib + abiraterone, talazoparib + enzalutamide, and niraparib + abiraterone.
This activity will provide expert contextualization of evidence from first-line mCRPC clinical trials exploring these combinations, including insights about the differentiation of both treatment and patient selection, as well as management of treatment-related toxicities. Given the differences in approvals and guidelines between the US and European context, this Ryder Cup themed Expert Panel Discussion will compare and contrast the approach in both regions, giving participants comprehensive education on …
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Paul Hunter, MD
It’s important to recognize that older adults are more susceptible to influenza infection—as well as increased severity of infection—than younger, healthier populations.1 Fortunately, there are vaccines available that can help prevent influenza in this aging population. But do the relative benefits and harms of higher-dose and adjuvanted vaccines, compared with one another and with other influenza vaccines, favor the use of any one or more of these vaccines over other age-appropriate options for people 65 and older?2 That's the exact question the CDC’s Advisory Committee on Immunization Practices (ACIP) sought to answer and what Dr. Charles Turck discusses with Dr. Paul Hunter, Associate Professor in the Department of Family Medicine and Community Health at the University of Wisconsin School of Medicine and Public Health.
References:
1. Centers for Disease Control and Prevention. Fly & People 65 Years and Older. Accessed August 16, 2022. https://www.cdc.gov/flu/highrisk/65over.htm.
2. National Center for Immunization & Respiratory Diseases. Advisory Committee on Influenza Practices. Influenza Vaccines for Older Adults: GRADE Summary. Accessed August 16, 2022.
USA-FLUD-22-0056 December 2022
Host: Jacob Sands, MD
Guest: Tomasz Beer, MD, FACP
Multi-cancer early detection tests are designed to detect multiple cancers from a single blood test. Could these tests help address some of the most common limitations associated with current cancer screening methods, like a lack of adherence and access? Joining Dr. Jacob Sands to discuss how multi-cancer early detection tests work and their potential impact on cancer screening is Dr. Tom Beer, Adjunct Professor of Medicine at the OHSU Knight Cancer Institute and the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Natalia Castillo Almeida, MD
Patients in urban communities often face challenges when accessing influenza vaccines. But there are ways we can help address those geographic and socioeconomic barriers. Joining Dr. Charles Turck to share key strategies for improving influenza vaccination rates in urban communities is Dr. Natalia Castillo, Assistant Professor in the Division of Infectious Diseases at University of Nebraska Medical Center.
Host: Kevin Cleveland, PharmD, ANP
Older adults face a variety of unique challenges that increase their risk of serious influenza infections. But fortunately, vaccinations can help address these challenges. Learn more with Dr. Kevin Cleveland, Associate Professor at the Idaho State University College of Pharmacy.
Host: Jennifer Caudle, DO
Guest: Carolyn Bridges, MD
We all know that influenza vaccinations can help prevent serious infections and save lives. But how often do you consider the underrecognized benefits of these vaccines—like how influenza vaccinations can be a cost-effective solution for both patients and the entire healthcare system? Joining Dr. Jennifer Caudle to discuss these underrecognized benefits and how we can educate patients about the benefits of influenza vaccination is Dr. Carolyn Bridges, Director of Adult Immunizations at Immunize.org.
Host: Christina Madison, BS, PharmD, BCACP, AAHIVP
In the midst of a potential tridemic between COVID-19, RSV, and influenza, it’s now more critical than ever to raise awareness among patients about the importance of flu vaccines. Here to provide counseling strategies for educating patients about flu vaccines is Dr. Christina Madison, Associate Professor of Pharmacy Practice at Roseman University of Health Sciences.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kimberly McKeirnan, Pharm.D., BCACP
Vaccination rates are much lower in rural communities compared to other regions, which has a big impact on patients and the larger healthcare system as a whole. So what are some of the factors contributing to this disparity, and what strategies can we use to address them? Joining Dr. Charles Turck to discuss how we can increase vaccination rates in rural communities is Dr. Kimberly McKeirnan, Director of the Center for Pharmacy Practice Research at Washington State University.
Host: Matt Birnholz, MD
Guest: David Canaday, MD
As we age, our immune system becomes weaker and is therefore unable to ward off infection as easily as in our younger years.1 This is particularly troublesome during flu season. In fact, the CDC’s Advisory Committee on Immunization Practices (ACIP) recently looked at flu vaccine data for adults aged 65 years and older, and they now recommend that this age group preferentially receive higher dose or adjuvanted vaccines over standard dose unadjuvanted vaccines when available.2 So what was the data that led to these updated recommendations? Joining Dr. Matt Birnholz to share those key findings and the role of adjuvanted vaccines like FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) in preventing influenza in older adults is Dr. David Canaday, Professor in the Division of Infectious Diseases & HIV Medicine at Case Western Reserve University in Cleveland.
Avoid use in patients who have experienced any severe allergic reactions to any component of the vaccine. For more risk information please see below or consult the Full US Prescribing Information for FLUAD® QUADRIVALENT here.
References:
1. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2(11):659-666.
2. Centers for Disease Control and Prevention. Past seasons estimated influenza disease …
Guest: Rishi D. Naik, MD, MSCI
Colorectal cancer may be more prevalent than you think, underscoring the importance of colorectal cancer screening. Join us as we explore the latest screening recommendations and available modalities with Dr. Rishi Naik, Assistant Professor of Medicine in the Department of Gastroenterology, Hepatology, and Nutrition at Vanderbilt University Medical Center in Nashville, Tennessee.
Host: Ayse Tuba Kendi, MD
Guest: A. Oliver Sartor, MD
Prostate cancer–specific antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the targeting of PSMA. With clinical research shifting paradigms for the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment options require adoption and effective application into clinical practice. PSMA has become an appealing target for diagnostic agents for imaging and therapeutic agents to treat mCRPC. Radionuclide emitters are being used for both cell surface expression of PSMA and the tumor microenvironment, and research has proven the therapeutic efficacy of PSMA-directed radioligand therapy (RLT).
In this educational activity, two experts will examine the role and rationale for PSMA targeted therapies and diagnostics—jointly known as theragnostics—as a revolutionary new approach to treating patients with advanced prostate cancer and will evaluate clinical trial data for PSMA-targeted RLT.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nick Kusnezov, MD
Can you balance locum tenens with a full-time career? To answer that question, Dr. Charles Turck is joined by board-certified orthopedic surgeon, Dr. Nicholas Kusnezov, to walk us through his journey from joining the military to locum tenens.
Host: Jennifer Caudle, DO
Guest: Roni Devlin, MD
As rates of burnout continue to rise in the healthcare community, how can help our female physicians combat it? Dr. Jennifer Caudle joins Infectious Disease Specialist, Dr. Roni Devlin, to discuss how we can prevent burnout for female physicians.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Lyudmila Bazhenova, MD
Guest: Benjamin Levy, MD
HER2-targeted therapies have demonstrated substantial survival benefits for patients with HER2-positive breast cancer. So can we use those agents for HER2-positive NSCLC? Join Dr. Lyudmila Bazhenova and Dr. Benjamin Levy as they discuss the latest data around emerging agents for HER2-positive NSCLC and the best way to identify these mutations in clinical practice.
Host: Hector O. Chapa, MD, FACOG
Guest: Naomi Whittaker, MD
The challenges that come with conception can be strenuous and emotionally draining. But with emerging tools and technology, there are many ways we can help our patients conceive naturally. Dr. Naomi Whittaker, an OB/GYN physician, joins Host Dr. Hector Chapa to share these strategies.
Host: Neilanjan Nandi, MD
Guest: Jean-Frederic Colombel, MD
There are over a half dozen newer and emerging classes of agents for ulcerative colitis. This abundance is great news for our patients, but it also increases the complexity of treatment. Listen in as Dr. Neil Nandi and Dr. Jean-Frederic Colombel explore the roles that these agents will play in the evolving treatment landscape.
Since the completion of this activity, results from the ELEVATE UC 52 study, a yearlong phase 3 trial of etrasimod in moderate to severe ulcerative colitis, were announced. Etrasimod is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator that showed positive 12- and 52-week results compared to placebo. Patients achieved statistically significant improvements in the co-primary endpoint of clinical remission at weeks 12 and 52 when compared to placebo. Statistically significant improvements were also attained in all key secondary endpoints at both 12 and 52 weeks. We will provide more data as the full results are published and presented in the future.
Host: Neilanjan Nandi, MD
Guest: David T. Rubin, MD
The proliferation of new classes of therapies for ulcerative colitis is affecting how we decide which treatments are most appropriate for our patients who are first- or second-line non-responders. This creates not only new challenges, but also new opportunities for all community gastroenterologists. Dr. Neil Nandi and Dr. David Rubin walk us through a case to highlight some of these challenges.
Since the completion of this activity, results from the ELEVATE UC 52 study, a yearlong phase 3 trial of etrasimod in moderate to severe ulcerative colitis, were announced. Etrasimod is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator that showed positive 12- and 52-week results compared to placebo. Patients achieved statistically significant improvements in the co-primary endpoint of clinical remission at weeks 12 and 52 when compared to placebo. Statistically significant improvements were also attained in all key secondary endpoints at both 12 and 52 weeks. We will provide more data as the full results are published and presented in the future.
Host: Rachel Caskey, MD, MAPP
Guest: Gwendolyn Ramirez
Vaccine hesitancy is a very challenging, and often tiring topic, for clinicians to address. Join Dr. Rachel Caskey in an engaging clinician-patient dialogue as she uses a dynamic and presumptive approach to overcome common vaccination challenges. What communication pearl will you use with your patients?
Host: John J. Russell, MD
Guest: Joseph E. Bavaria, MD
Featuring a wide range of disciplines and a new approach to comprehensive care, what do we need to know about the Aorta Center at Penn Medicine? Dr. John Russell is joined by Dr. Joseph E. Bavaria to dive into this aortic program and discuss a new approach to comprehensive care.
Host: Jacob Sands, MD
Guest: Yasmin Jayasinghe, FRANZCOG, PhD
Cancer treatment can impact fertility outcomes for individuals throughout the U.S. as well as around the globe, which is why the emerging field of oncofertility is here to help male and female patients navigate their fertility options before and after their cancer treatments. So what can we learn from oncofertility services and efforts from other countries around the world? Joining Dr. Jacob Sands to share her global viewpoints on the field of oncofertility is Dr. Yasmin Jayasinghe, Director of the Oncofertility Program at the Royal Children’s Hospital.
Host: Jacob Sands, MD
Guest: Yasmin Jayasinghe, FRANZCOG, PhD
Pediatric and adolescent oncofertility patients are cared for differently than adult patients. That’s why Dr. Yasmin Jayasinghe, Director of the Oncofertility Program at the Royal Children’s Hospital, is here to give us an overview of the available procedures for pediatric patients and the key considerations that go along with them.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kathryn Gallagher, MS, RN, BSN
Guest: Kate Newcomb-DeSanto, MSN, RN, MSW
What does Penn Medicine’s newly-opened patient room facility have to offer? Dr. Charles Turck is joined by Penn Medicine Clinical Advisors Kathy Gallagher and Kate Newcomb-DeSanto to discuss the new pavilion and how it's revolutionizing patient care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Host: Jacob Sands, MD
Guest: Suneeta Senapati, MD, MSCE
Guest: Mindy Christianson, MD
Patients undergoing treatments such as chemotherapy may be at significant risk of impairment or inability to have children later in life. This risk impacts both men and women equally, but fortunately, the field of oncofertility can help guide patients as they navigate their fertility options prior to cancer treatment. Here to share their insights on this emerging field with Dr. Jacob Sands are Dr. Mindy Christianson and Dr. Suneeta Senapati.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Jennifer Caudle, DO
Guest: Erik Munson, Ph.D
Mycoplasma genitalium (M. gen) is an STI that shares similar health consequences to chlamydia and gonorrhea. Further complicating this health threat is the fact that there’s been little guidance on how to manage this new pathogen until recently when the 2021 STI Treatment Guidelines were released. Joining Dr. Jennifer Caudle to talk about M. gen and why the guidelines recommend the use of nucleic acid amplification tests for the diagnosis of this pathogen is Dr. Erik Munson, an Assistant Professor of Clinical Laboratory Science at Marquette University.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Charles P. Vega, MD
Guest: Robert O. Roswell, MD, FACC, FACP
Diversifying our physician workforce so that it is more racially, ethnically, and geographically balanced can ultimately have a positive impact on community health. Join us as two experts discuss how pipeline programs reaching children as early as elementary school can help ensure workplace diversity. Also find out how clinicians can be advocates for their patients by helping to disentangle them from structural inequities and working towards policy changes. There’s a lot than can be done to provide more balanced care, but we need to look beyond simple fixes to the root causes of the issues. So find your bandwidth – that’s what you can do today – and discover why it’s so important to move upstream to solve the problems manifesting downstream.
Host: Charles P. Vega, MD
Guest: Lionel Phillips, MBA
Learn why diversity in clinical trials is so important to community health. Two experts discuss the key role that trusted messengers play in enrollment, why it is critical to break the cycle of medical mistrust, and the downstream effect of a lack of diversity in clinical trials.
Host: Charles P. Vega, MD
Guest: Candice Taylor Lucas, MD, MPH, FAAP
What is cultural humility, and how can it be incorporated into clinical practice? How does your patient's culture impact their health behaviors, and why does your culture matter?
Listen in as two leading experts navigate concerns surrounding cultural humility and emphasize the importance of empathy, awareness, and advocacy. Discover ways to integrate small but important changes into your clinical practice to help bridge communication gaps and enable your patients to thrive.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Emily Louise Johnson, MD
According to recent estimates, between 150,000 and 450,000 transgender patients have epilepsy. And as that number is only expected to grow, Assistant Professor of Neurology at Johns Hopkins School of Medicine Dr. Emily Johnson shares key considerations for treating transgender patients with epilepsy.
Host: Neilanjan Nandi, MD
Guest: Jordan E. Axelrad, MD, MPH
Many IBD patients and clinicians shy away from the topic of sexual health—and understandably so. Talking about sex in the clinic sadly remains a taboo, and there’s not many research studies exploring IBD and sexual health to use for guidance. But sexuality and intimacy are vital matters to discuss with our patients, which is why Dr. Jordan Axelrad joins Dr. Neil Nandi to share how we can facilitate an open and honest conversation with patients about their sexual health.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
There is clinical trial-supported evidence for the use of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with heart failure and reduced ejection fraction. RAASi therapy improves both morbidity and mortality outcomes, and its use is now recommended in published guidelines. However, the achievement of target dosing is often limited or interrupted due to the development of hyperkalemia.
In this case-based activity, Drs. Javed Butler and Ileana Piña discuss the importance of optimizing RAASi therapy in patients with heart failure and how the use of potassium binders can help accomplish this goal. They will also review the risks and benefits of potassium binders, in addition to both short- and long-term use of these agents in the treatment of patients with heart failure.
Host: Loretta J. Nastoupil, MD
Guest: John P. Leonard, MD
Recent clinical trial evidence supports the use of available and emerging options in relapsing/refractory follicular lymphoma. In this case-based activity, Dr. Loretta Nastoupil and Dr. John Leonard discuss the importance of testing for EZH2 mutations in follicular lymphoma, choosing the appropriate treatment option for each patient, and how to minimize risk to improve patient outcomes.
Host: Loretta J. Nastoupil, MD
Guest: Gilles Salles, MD
Follicular lymphoma (FL) is an incurable neoplasm that is frequently associated with relapse and refractory (R/R) disease. In this activity, Drs. Loretta Nastoupil and Gilles Salles will review the role of EZH2 modulation in FL and explain the role that EZH2 inhibition can play in R/R disease. They will also discuss the many available oral therapeutic options and emerging therapies on the horizon, recent data from those clinical trials, and where these therapies will fit into clinical practice.
Host: Loretta J. Nastoupil, MD
Guest: Matthew J. Matasar, MD
The epigenetic modulator EZH2 is known to play a crucial role in mediating the lymphomagenesis of follicular lymphoma (FL), and the inhibition of EZH2 in the relapsing/refractory disease setting has shown efficacy. In this activity, Drs. Matasar and Nastoupil discuss the role of EZH2 in the pathobiology of FL, emphasize the need to test for mutations in EZH2 in FL, and explore the potential of targeting EZH2 in different settings of FL treatment.
Host: Matthew R. Weir, MD
Guest: Gates B. Colbert, MD, FASN
Guest: Robert Toto, MD
Hyperkalemia (HK) is a major impediment to optimizing RAASi therapy in various patient populations. Fortunately, newer treatments are now available to mitigate this adverse effect. In this chapterized activity, Drs. Colbert, Toto, and Weir discuss strategies to manage a patient with chronic kidney disease (CKD) and resistant hypertension. Find out who is at risk for HK and explore the use of a potassium binder as both a short- and long-term solution.
Guest: Michael R. Shafique, MD
Here to give us a look at the unique genetic characteristics and prognostic implications for male and female patients with non-small cell lung cancer who harbor the RET fusion gene is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.
Host: Matt Birnholz, MD
Guest: Christopher P. Evans, M.D., F.A.C.S.
Guest: Maha Hussain, MD, FACP, FASCO
Prostate cancer is one of the most common cancers in men in the United States. In a program sponsored by Astellas and Pfizer, Drs. Maha Hussain and Christopher Evans discuss the history and how care is evolving for men with metastatic prostate cancer and non-metastatic castration-resistant prostate cancer.
This program is intended for United States health care professionals only. Drs. Hussain and Evans have recevied compensation from Astellas and Pfizer for their time.
074-0391-PM
Host: Javed Butler, MD, MBA, MPH
Guest: Paul W. Armstrong, MD
Finding the optimal treatment strategy for patients with worsening heart failure with reduced ejection fraction (HFrEF) can be challenging, and long-term outcomes are poor. Can newer therapies and novel mechanisms of action finally help close the treatment gap for these patients? Join Drs. Javed Butler and Paul Armstrong as they explore these new mechanisms of action and provide practical insights into incorporating newly approved therapies into an overall HFrEF treatment plan.
Host: Joel L. Cohen, MD
The differences between biostimulators and dermal fillers are simple yet critically important to their safe and successful use. With the help of 2D animation, Dr. Joel Cohen presents different techniques to optimize results in patients and minimize the risk of adverse effects.
Host: Joel L. Cohen, MD
Guest: Jason D. Bloom, MD
Dr. Joel Cohen and Dr. Jason Bloom discuss the importance of neuromodulator selection and accurate dosing for the glabella and upper face. Dr. Bloom takes us through a patient demonstration of optimal injection techniques and dosing while addressing strategies to minimize the risk for adverse events.
Host: Joel L. Cohen, MD
Guest: Carolyn I. Jacob, MD, FAAD
What does the future hold for aesthetics? The 4 four available neuromodulators share a similar mechanism of action and efficacy profiles, but they each have their own unique characteristics, and now an emerging agent is about to enter the scene. Dr. Joel Cohen and Dr. Carolyn Jacob discuss the subtle differences among neuromodulators and the importance of dosing for duration, specifically for the glabella and upper face. They also explore potential adverse events and strategies to minimize your patients’ risks.
Host: Andrew Alexis, MD, MPH
Guest: Linda Stein Gold, MD
Depression, anxiety, failure to thrive, unemployment, low self-esteem, and suicidal ideation. What could possibly be contributing to all of these consequences? The culprit is acne—didn’t expect that, did you? Hear from dermatologists Dr. Andrew Alexis and Dr. Linda Stein Gold as they discuss the proper assessment of acne, its location—particularly beyond the face—and the differences to keep in mind when assessing skin of color. Faculty also examine the role that selective retinoid therapies play in treating acne and preventing the development of both the physical and psychological scars associated with this condition.
Host: Joshua Sharfstein, MD
Guest: Sabra L. Klein, PhD
Host: Stephanie Desmon
Guest: Rosemary Morgan, PhD
Globally, more men are dying from COVID-19 than women. But is this due to sex (biological differences), gender (social and contextual differences), or something else entirely? Stephanie Desmon talks to virologist Sabra Klein and social scientist Rosemary Morgan about risk factors associated with COVID-19.
Published April 6, 2020
Host: Paul Doghramji, MD
Guest: Alexander W. Pastuszak, MD, PhD
Put your knowledge of male infertility diagnosis and treatment strategies to the test with Dr. Alexander Pastuszak, an Assistant Professor at the University of Utah School of Medicine, as he breaks down its common causes and how we can improve care for our male patients.
Host: Paul Doghramji, MD
Guest: Alexander W. Pastuszak, MD, PhD
Even though hypogonadism is common among men, there are still some misconceptions surrounding it. So to learn more about how we can better diagnose and treat hypogonadism in our male patients, Dr. Paul Doghramji sits down with Dr. Alexander Pastuszak, an Assistant Professor at the University of Utah School of Medicine.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Alexander W. Pastuszak, MD, PhD
While Peyronie’s disease isn’t the most comfortable topic to talk about with your male patients, avoiding it only fuels its under-recognition. So joining Dr. Paul Doghramji to discuss conversation-starter strategies—and what to do once you have that conversation and reach a diagnosis—is Dr. Alexander Pastuszak, a urologist at the University of Utah School of Medicine in Salt Lake City who specializes in the treatment of male infertility and sexual dysfunction.
Host: Matt Rosenberg, MD
Guest: Aiden Harrington, ANP, CNM
Current CDC Treatment Guidelines include transgender men and women as special populations. These guidelines recommend risk assessment based on current anatomy and sexual behaviors and screening for asymptomatic STIs based on the patient's history and sexual practices.
At a recent live event recorded in Chicago, moderator Dr. Matt T. Rosenberg welcomes Aiden Harrington, ANP, CNM from Howard Brown Health in Chicago, Illinois. Topics covered include health risks in the LGBTQ community, STI screening and treatment, and how to discuss sexuality with your patients.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Robert Kloner, Vice President of Translation at Huntington Medical Research Institutes and Professor of Medicine in the Cardiovascular Division of Keck School of Medicine at the University of Southern California.
Dr. Kloner discusses the cardiovascular risk factors associated with erectile dysfunction, safety and efficacy of erectile disfunction drugs, and benefits vs risks of supplementing with testosterone.
Host: Brian P. McDonough, MD, FAAFP
In a survey released by the American Academy of Family Physicians (AAFP), nearly half of men reported that their health was "good" or "excellent." This marked a dramatic increase in health perceptions from men over the past decade, despite the fact that more men now live with chronic conditions such as hypertension and diabetes than ever before. What does this discrepancy between perceptions and realities tell us about the state of health care for men in America?
Joining Dr. Brian McDonough to discuss special considerations and primary care priorities for men is Dr. John Meigs, practicing generalist and President-Elect of the AAFP.
Host: Brian P. McDonough, MD, FAAFP
Guest: Charles N. Walker, MD
Dr. Charles Walker, Assistant Professor of Surgery in the Department of Urology at Yale University School of Medicine, shares clinical insights about penile prostheses, such as inflatable versus malleable devices, used as surgical gold standards to treat erectile dysfunction.
Host: Shira Johnson, MD
Guest: Charles N. Walker, MD
Dr. Shira Johnson speaks with Dr. Charles Walker, Assistant Professor of Surgery in the Department of Urology at Yale University School of Medicine. The two focus on erectile dysfunction as a common complication for patients dealing with diabetes and heart disease, and ways that clinicians can help patients manage this problem through lifestyle modifications. Dr. Walker also introduces emerging pathophysiological understandings of ED as a potential predictor of diabetes.
Host: Paul Rokuskie
Recent studies have uncovered sex differences in both the neurobiology and phenotypical presentations of autism. These emerging understandings for how autism manifests uniquely in girls vs boys may radically change the way autism spectrum disorder is clinically perceived, improving diagnostic sensitivity and personalizing therapies.
Joining host Paul Rokuskie to discuss this line of research developments in autism spectrum disorder is Dr. Kaustubh Supekar, research scientist in the Department of Psychiatry at Stanford University School of Medicine.
[Read the Article]
The popularity of testosterone supplementation among older men has increased substantially over the past decade. However, the risks and benefits of long-term administration are still unclear. A new study examined whether using testosterone supplements affected the development of atherosclerosis (hardening of arteries), which is linked to heart attack and stroke.
Researchers from Brigham and Women's Hospital in Boston studied more than 300 men who were sixty years of age and older, in relatively good health, and had low or low-normal testosterone levels. Half the men applied a testosterone gel daily to the skin for three years, while the other half were given a placebo gel. During the course of the trial, hardening of the arteries was measured in the carotid and coronary arteries, which supply the brain and heart.
Results were that during the three year study, there was no significant effects in terms of hardening of the carotid or coronary arteries. Testosterone supplementation also did not improve overall sexual function or health-related quality of life.
[Watch more videos of The JAMA Report]
JAMA Report videos provided pursuant to license. ©2015 American Medical Association, publisher of JAMA® and The JAMA Network® …
Host: Lee Freedman, MD
Given the multitude of concerns a male patient with cancer must deal with, sexual dysfunction and infertility are two such concerns that often gets bypassed by clinicians addressing more "priority" issues. What kinds of challenges do these patients deal with, and how can physicians better assess and manage them? Joining Dr. Freedman to discuss sexual health and fertility in male cancer survivors is Dr. Puneet Masson, Director of the Male Infertility Program and Assistant Professor of Urology at Penn Medicine.
Host: Bruce Japsen
Guest: Mark Frohlich, MD
The cancer treatment Provenge, known as a "therapeutic vaccine," was approved by the Food and Drug Administration in April, 2010 as a novel way to attack prostate tumors. But this is more than the story of a new treatment. Host Bruce Japsen learns about the long path to FDA approval for this unique therapy that some see as a watershed development in oncology, from Dr. Mark Frohlich, senior vice president of clinical affairs and chief medical officer of Dendreon Corporation, the Seattle-based biotech company that manufactures Provenge.
Host: Lee Freedman, MD
Guest: Michael Hildebrand, PhD
Researchers have discovered a CATSPER gene mutation that may lead to development of a male infertility treatment, as well as a male contraceptive. Are we really another step closer to developing a male contraceptive, and when might an oral contraceptive be available for men? Join host Dr. Lee Freedman as he talks with Dr. Michael Hildebrand, fellow in the department of otolaryngology at the Carver College of Medicine, University of Iowa, about this exciting new genetic discovery, and how it might lead to the development of a male contraceptive.
Host: Maurice Pickard, MD
Guest: Abraham Morgentaler, MD
It is widely believed that testosterone therapy for men with low testosterone can lead to an increased risk of prostate cancer. Dr. Abraham Morgentaler, associate clinical professor of urology at Harvard Medical School and author of the book Testosterone for Life, recalls the fascinating story of how this idea of high testosterone levels increasing the risk of prostate cancer originated, and suggests that in fact, the opposite might be true. What evidence supports boosting testosterone levels in men with low levels of the hormone, and that this might not raise a man's risk of developing prostate cancer? Hosted by Dr. Maurice Pickard.
Host: Shira Johnson, MD
Guest: Stephen Schwartz, PhD
Approximately 8000 men are diagnosed every year with testicular cancer in the United States. A first-of-its-kind study looked at whether or not marijuana use increases the risk. Dr. Stephen Schwartz, one of the researchers on the study and professor of epidemiology at the University of Washington, discusses his findings with host Dr. Shira Johnson. The two discuss how the research was conducted, who took part, and what needs to be done in the future to find more definitive answers.
Host: Mark Nolan Hill, MD
Guest: Craig Nichols, MD
When patients think of testicular cancer, they immediately think of two ramifications: the impact on their fertility and on their sexuality. Are these concerns well-founded? How should we counsel our patients on these issues? Dr. Craig Nichols, medical director of lymphoma and testicular cancer research at Providence Portland Medical Center in Portland, Oregon, and an internationally respected expert on testicular cancer, explores these issues with host Dr. Mark Nolan Hill. How will the concerns of our patients change as we continue to improve our understanding and our treatment of testicular cancer?
Host: Mark Nolan Hill, MD
Guest: Craig Nichols, MD
Diagnosed in thousands of American men each year, testicular cancer has proven highly sensitive to current treatment regimens. Host Dr. Mark Nolan Hill evaluates the most common therapies for testicular cancer with Dr. Craig Nichols, medical director of lymphoma and testicular cancer research at Providence Portland Medical Center in Portland, Ore., and an internationally respected expert on testicular cancer. Are there significant side effects to the present therapies? Further, keeping in mind the possibility of a recurrent disease, and the accordant need for proper follow-up measures, Dr. Nichols evaluates strategies for coordinating care between medical oncologists and primary care physicians.
Host: Mark Nolan Hill, MD
Guest: Craig Nichols, MD
If detected in its early stages, we have great success in curing testicular cancer. What are our most effective screening measures? How should we instruct our patients to be vigilant with their own self-exams, or is this the best approach? Dr. Craig Nichols, medical director of lymphoma and testicular cancer research at Providence Portland Medical Center in Portland, Ore., and an internationally respected expert on testicular cancer, joins host Dr. Mark Nolan Hill to review our most effective defenses against this disease.
Host: Leslie P. Lundt, MD
Guest: Diann Ackard, PhD
When we hear that a patient has an eating disorder, we almost always think of a female. Yet adolescent boys do have disordered eating. Might knowing the risk factors help us target our interventions? Eating disorders expert Dr. Diann Ackard joins host Dr. Leslie Lundt as they discuss gender differences in eating disorders.
Host: Larry Kaskel, MD
Guest: Elizabeth Tieman, MD
Work-life balance: how many of us can say we have it, let alone come close to having it? Board-certified radiologist Dr. Betsy Tieman is one healthcare professional who can say she achieved work-life balance by leaving private practice where she was working 14 hours a day to take advantage of locum tenens work, which also enabled her to train and compete in triathlons.